# Combination Therapy of Senaparib and Bevacizumab for First-line Maintenance Therapy in Newly Diagnosed Advanced Homologous Recombination Proficient Ovarian Cancer Based on Exosome Protein Marker

> **NCT07120451** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fudan University** · enrollment: 37 (estimated)

## Conditions studied

- Advanced Ovarian Cancer

## Interventions

- **DRUG:** Senaparib
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT07120451
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-10-10
- **Primary completion:** 2026-10-31
- **Final completion:** 2028-10-31
- **Target enrollment:** 37 (ESTIMATED)
- **Last updated:** 2025-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07120451

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07120451, "Combination Therapy of Senaparib and Bevacizumab for First-line Maintenance Therapy in Newly Diagnosed Advanced Homologous Recombination Proficient Ovarian Cancer Based on Exosome Protein Marker". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT07120451. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*